AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39175843 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz-based ART for 1-7 days prior to randomization
Number of subjects: 833
Study 39175843 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal nevirapine +/- zidovudine prophylaxis
Number of subjects: 833
Study 39175910 — intervention group
Group type: EXPERIMENTAL
Intervention: SBIRT implementation for adolescent AOD use
Number of subjects: 430
Study 39175923 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time digital assessment tools
Number of subjects: 0
Study 39175939 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-SENSE Score
Number of subjects: 200
Study 39175939 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-SENSE Score with auxiliary diagnostic methods
Number of subjects: 200
Study 39176029 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat vegan diet
Number of subjects: 62
Study 39176029 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean diet
Number of subjects: 62
Study 39176240 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on low dose Astragalus membranaceus (AM) for 24 weeks
Number of subjects: 66
Study 39176240 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on high dose Astragalus membranaceus (AM) for 24 weeks
Number of subjects: 66
Study 39176240 — intervention group
Group type: COMPARATOR
Intervention: Routine care for 24 weeks
Number of subjects: 66
Study 39176240 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on low dose Astragalus membranaceus (AM)
Number of subjects: 66
Study 39176240 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on high dose Astragalus membranaceus (AM)
Number of subjects: 66
Study 39176240 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 66
Study 39176240 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (low dose AM, high dose AM, routine care)
Number of subjects: 66
Study 39177285 — intervention group
Group type: EXPERIMENTAL
Intervention: ORIC-101 with nab-paclitaxel
Number of subjects: 83
Study 39177285 — intervention group
Group type: COMPARATOR
Intervention: Control group (taxane-based regimen)
Number of subjects: 83
Study 39177431 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumonia patients in PICU
Number of subjects: 846
Study 39177431 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 846
Study 39177431 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Index of Mortality 3 score
Number of subjects: 846
Study 39177431 — intervention group
Group type: EXPERIMENTAL
Intervention: Drowsiness
Number of subjects: 846
Study 39177553 — intervention group
Group type: EXPERIMENTAL
Intervention: AccuFFRct
Number of subjects: 339
Study 39177596 — intervention group
Group type: EXPERIMENTAL
Intervention: Gantenerumab (up to 1,200 mg every 4 weeks)
Number of subjects: 225
Study 39177931 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor (dapagliflozin) with alpelisib
Number of subjects: 93
Study 39177931 — intervention group
Group type: COMPARATOR
Intervention: Alpelisib alone (control)
Number of subjects: 93
Study 39178000 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet group
Number of subjects: 59
Study 39178000 — intervention group
Group type: COMPARATOR
Intervention: No tourniquet group
Number of subjects: 59
Study 39178001 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician training in shared decision-making (SDM) and electronic previsit reminders
Number of subjects: 466
Study 39178001 — intervention group
Group type: COMPARATOR
Intervention: Reminders only (comparator group)
Number of subjects: 466
Study 39178001 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician training in SDM
Number of subjects: 466
Study 39178001 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 466
Study 39178001 — intervention group
Group type: COMPARATOR
Intervention: Comparator group
Number of subjects: 466
Study 39178048 — intervention group
Group type: EXPERIMENTAL
Intervention: Burpees (T30: 32.2 kcals/min, T45: 40.7 kcals/min)
Number of subjects: 10
Study 39178048 — intervention group
Group type: EXPERIMENTAL
Intervention: Jumping Jacks (T30: 23.1 kcals/min, T45: 22.8 kcals/min)
Number of subjects: 10
Study 39178048 — intervention group
Group type: EXPERIMENTAL
Intervention: Push-ups (T30: 22.0 kcals/min, T45: 24.9 kcals/min)
Number of subjects: 10
Study 39178048 — intervention group
Group type: EXPERIMENTAL
Intervention: Squat (T30: 19.9 kcals/min, T45: 23.2 kcals/min)
Number of subjects: 10
Study 39178048 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-leg Squat (T30: 19.8 kcals/min, T45: 21.2 kcals/min)
Number of subjects: 10
Study 39178048 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward Lunge (T30: 18.6 kcals/min, T45: 22.0 kcals/min)
Number of subjects: 10
Study 39178048 — intervention group
Group type: EXPERIMENTAL
Intervention: Plank (T30: 11.3 kcals/min, T45: 12.6 kcals/min)
Number of subjects: 10
Study 39178051 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Seizure Therapy (MST)
Number of subjects: 67
Study 39178051 — intervention group
Group type: COMPARATOR
Intervention: Electroconvulsive Therapy (ECT)
Number of subjects: 67
Study 39178062 — intervention group
Group type: EXPERIMENTAL
Intervention: Kettlebell swing (KBS) group (n = 21)
Number of subjects: 41
Study 39178062 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON; n = 20)
Number of subjects: 41
Study 39178168 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy dressings (Prevena™ and PICO™)
Number of subjects: 2013
Study 39178168 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical dressings (control arm)
Number of subjects: 2013
Study 39178272 — intervention group
Group type: EXPERIMENTAL
Intervention: Balika Bodhu intervention (empowerment and social norm based intervention)
Number of subjects: 1120
Study 39178272 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1120
Study 39178291 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive transcutaneous auricular Vagus nerve stimulation (taVNS)
Number of subjects: 0
Study 39178291 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 39178369 — intervention group
Group type: EXPERIMENTAL
Intervention: VIGex-Hot
Number of subjects: 76
Study 39178369 — intervention group
Group type: COMPARATOR
Intervention: I-Cold/Cold
Number of subjects: 76
Study 39178369 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline VIGex classification with ΔctDNA
Number of subjects: 76
Study 39178640 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher habitual degree of weight loss
Number of subjects: 62
Study 39178640 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional regulation during weight maintenance
Number of subjects: 62
Study 39179000 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient Palliative Care (OPC) - one visit a month for six months
Number of subjects: 603
Study 39179000 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient Palliative Care (OPC)
Number of subjects: 603
Study 39179051 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent airflow obstruction (PAO)
Number of subjects: 11886
Study 39179051 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 11886
Study 39179051 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 11886
Study 39179051 — intervention group
Group type: EXPERIMENTAL
Intervention: Ever smoking
Number of subjects: 11886
Study 39179051 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased number of pack years
Number of subjects: 11886
Study 39179051 — intervention group
Group type: EXPERIMENTAL
Intervention: Not being breastfed
Number of subjects: 11886
Study 39179051 — intervention group
Group type: EXPERIMENTAL
Intervention: Ever diagnosis of asthma
Number of subjects: 11886
Study 39179206 — intervention group
Group type: EXPERIMENTAL
Intervention: FIBCRO (sourdough-leavened croissant enriched with dietary fibers, 4.8 g/100 g)
Number of subjects: 32
Study 39179206 — intervention group
Group type: COMPARATOR
Intervention: CONCRO (control croissant, dietary fibers 1.3 g/100 g)
Number of subjects: 32
Study 39179206 — intervention group
Group type: EXPERIMENTAL
Intervention: FIBCRO
Number of subjects: 32
Study 39179207 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic (400 mg/100 mL GOS and L. reuteri DSM 17938)
Number of subjects: 82
Study 39179252 — intervention group
Group type: COMPARATOR
Intervention: SBP <120 mm Hg (reference)
Number of subjects: 2608
Study 39179252 — intervention group
Group type: COMPARATOR
Intervention: SBP 120-129 mm Hg
Number of subjects: 2608
Study 39179252 — intervention group
Group type: COMPARATOR
Intervention: SBP 130-139 mm Hg
Number of subjects: 2608
Study 39179252 — intervention group
Group type: COMPARATOR
Intervention: SBP ≥140 mm Hg
Number of subjects: 2608
Study 39179252 — intervention group
Group type: COMPARATOR
Intervention: SBP ≥140 mm Hg in women
Number of subjects: 2608
Study 39179252 — intervention group
Group type: COMPARATOR
Intervention: SBP ≥140 mm Hg in men
Number of subjects: 2608
Study 39179255 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICIs) including anti-PD-1 (79.3%), anti-PD-L1 (17.9%), combination of anti-PD-1 and anti-CTLA-4 (2.1%), anti-PD-1 with anti-VEGFR (0.7%)
Number of subjects: 140
Study 39179255 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICIs)
Number of subjects: 140
Study 39179257 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozoralizumab with methotrexate (MTX)
Number of subjects: 521
Study 39179257 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozoralizumab without MTX
Number of subjects: 521
Study 39179257 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozoralizumab
Number of subjects: 521
Study 39179363 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) and strength exercise for 12 weeks
Number of subjects: 87
Study 39179363 — intervention group
Group type: COMPARATOR
Intervention: Moderately intensive physical activity, ≥150 min/week (Control Group)
Number of subjects: 87
Study 39179458 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg dapagliflozin/100 mg sitagliptin fixed-dose combination (FDC)
Number of subjects: 46
Study 39179458 — intervention group
Group type: COMPARATOR
Intervention: Individual component (IC) tablets of dapagliflozin and sitagliptin
Number of subjects: 46
Study 39179638 — intervention group
Group type: EXPERIMENTAL
Intervention: S-MDMA (125 mg)
Number of subjects: 24
Study 39179638 — intervention group
Group type: EXPERIMENTAL
Intervention: R-MDMA (125 mg and 250 mg)
Number of subjects: 24
Study 39179638 — intervention group
Group type: EXPERIMENTAL
Intervention: S-MDMA
Number of subjects: 24
Study 39179638 — intervention group
Group type: EXPERIMENTAL
Intervention: R-MDMA (125 mg)
Number of subjects: 24
Study 39179638 — intervention group
Group type: EXPERIMENTAL
Intervention: R-MDMA (250 mg)
Number of subjects: 24
Study 39179638 — intervention group
Group type: EXPERIMENTAL
Intervention: R-MDMA
Number of subjects: 24
Study 39179638 — intervention group
Group type: COMPARATOR
Intervention: S-MDMA, MDMA, R-MDMA
Number of subjects: 24
Study 39179700 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (Group-1, n=110)
Number of subjects: 350
Study 39179700 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (Group-2, n=129)
Number of subjects: 350
Study 39179700 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group-3, n=111)
Number of subjects: 350
Study 39179855 — intervention group
Group type: EXPERIMENTAL
Intervention: CyberRwanda facilitated arm (peer-led clubs plus tablet access)
Number of subjects: 6078
Study 39179855 — intervention group
Group type: EXPERIMENTAL
Intervention: CyberRwanda self-service arm (self-guided access on tablets)
Number of subjects: 6078
Study 39179855 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 6078
Study 39179863 — intervention group
Group type: EXPERIMENTAL
Intervention: Tislelizumab combined with cisplatin and 5-fluorouracil (induction therapy)
Number of subjects: 47
Study 39179948 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Number of subjects: 20
Study 39179982 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution-Focused Brief Therapy (SFBT)
Number of subjects: 80
Study 39179982 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 80
Study 39180036 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Diabetes Prevention Program (DPP) outreach
Number of subjects: 1473
Study 39180036 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of outreach by VA sites
Number of subjects: 1473
Study 39180036 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual DPP
Number of subjects: 1473
Study 39180108 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent training program led by trained parent-teacher facilitator pairs
Number of subjects: 500
Study 39180108 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 500
Study 39180187 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with endocrine therapy (bicalutamide for 4 weeks and abiraterone for 2 years)
Number of subjects: 0
Study 39180325 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06425090 vaccine (3 doses at 0, 1, and 6 months)
Number of subjects: 17535
Study 39180326 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota, live-jslm (REBYOTA) administered rectally within 24-72h of antibiotic completion.
Number of subjects: 793
Study 39180326 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota, live-jslm (REBYOTA) administered rectally.
Number of subjects: 793
Study 39180372 — intervention group
Group type: EXPERIMENTAL
Intervention: Head and Neck Patient Symptom Checklist (HNSC)
Number of subjects: 522
Study 39180419 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring for late-onset giant cell arteritis (GCA) using vascular ultrasonography and FDG-PET/CT scans during clinical visits at weeks 8 and 10, and follow-up at one year.
Number of subjects: 62
Study 39180419 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline assessments including vascular ultrasonography and FDG-PET/CT scans.
Number of subjects: 62
Study 39180711 — intervention group
Group type: EXPERIMENTAL
Intervention: Full Body Blue device (453 nm)
Number of subjects: 20
Study 39180809 — intervention group
Group type: EXPERIMENTAL
Intervention: Duchenne muscular dystrophy (DMD) group
Number of subjects: 68
Study 39180809 — intervention group
Group type: EXPERIMENTAL
Intervention: Duchenne muscular dystrophy (DMD) group with distal site mutation
Number of subjects: 68
Study 39180809 — intervention group
Group type: COMPARATOR
Intervention: Typically developing children (control group)
Number of subjects: 68
Study 39180960 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term fasting (LF)
Number of subjects: 40
Study 39180989 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI + sarcosine
Number of subjects: 60
Study 39180989 — intervention group
Group type: COMPARATOR
Intervention: SSRI + placebo
Number of subjects: 60
Study 39181036 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified malnutrition diagnosis (GLIM)
Number of subjects: 269
Study 39181036 — intervention group
Group type: EXPERIMENTAL
Intervention: Low albumin concentration
Number of subjects: 269
Study 39181036 — intervention group
Group type: EXPERIMENTAL
Intervention: Low handgrip strength
Number of subjects: 269
Study 39181036 — intervention group
Group type: EXPERIMENTAL
Intervention: Low muscle radiodensity
Number of subjects: 269
Study 39181036 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined parameters
Number of subjects: 269
Study 39181037 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA/DHA supplementation (2.0 g daily for 10 weeks)
Number of subjects: 46
Study 39181037 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB + EPA/DHA supplementation (3.0 g Ca-HMB daily for 10 weeks)
Number of subjects: 46
Study 39181037 — intervention group
Group type: COMPARATOR
Intervention: Placebo (soy + corn oil for EPA/DHA and maltodextrin for HMB)
Number of subjects: 46
Study 39181168 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral agents
Number of subjects: 1152
Study 39181206 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intake of green leafy vegetables (≥2.7 servings/week compared with none)
Number of subjects: 2697
Study 39181206 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher fish intake (≥ two 4-ounce servings/week compared with <2)
Number of subjects: 2697
Study 39181206 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein/zeaxanthin (LZ) intake (≥2 mg/day compared with <2)
Number of subjects: 2697
Study 39181206 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intake of ω-3 fatty acids (≥0.7 g/week compared with <0.7)
Number of subjects: 2697
Study 39181214 — intervention group
Group type: EXPERIMENTAL
Intervention: Early PPG (measured 24-72 hours after TIPS)
Number of subjects: 466
Study 39181214 — intervention group
Group type: EXPERIMENTAL
Intervention: Late PPG (measured 1 month after TIPS)
Number of subjects: 466
Study 39181214 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate PPG (measured immediately after TIPS)
Number of subjects: 466
Study 39181214 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeting a post-TIPS PPG of 11-14 mmHg
Number of subjects: 466
Study 39181214 — intervention group
Group type: EXPERIMENTAL
Intervention: PPG measured 24-72 hours after TIPS
Number of subjects: 466
Study 39181325 — intervention group
Group type: EXPERIMENTAL
Intervention: Purity Independent Subtyping of Tumors (PurIST) algorithm using array-based NanoString nCounter Elements XT technology
Number of subjects: 74
Study 39181325 — intervention group
Group type: COMPARATOR
Intervention: RNA sequencing (RNAseq)
Number of subjects: 74
Study 39181422 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab (CAN) 3 mg/kg
Number of subjects: 57
Study 39181422 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 57
Study 39181422 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab (CAN)
Number of subjects: 57
Study 39181426 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Calorie Restriction (ICR) - 5:2 diet
Number of subjects: 72
Study 39181426 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-Care (SOC) diet - 80% of the recommended calorie intake
Number of subjects: 72
Study 39181426 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Calorie Restriction (ICR) - 5:2 diet (in patients with obesity)
Number of subjects: 72
Study 39181426 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-Care (SOC) diet (in patients with obesity)
Number of subjects: 72
Study 39181426 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Calorie Restriction (ICR) - 5:2 diet (in patients without obesity)
Number of subjects: 72
Study 39181426 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-Care (SOC) diet (in patients without obesity)
Number of subjects: 72
Study 39181426 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-Care (SOC) diet
Number of subjects: 72
Study 39181426 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Calorie Restriction (ICR) and Standard-of-Care (SOC) diet
Number of subjects: 72
Study 39181485 — intervention group
Group type: EXPERIMENTAL
Intervention: POLARx cryoballoon (CB) ablation
Number of subjects: 429
Study 39181556 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with a racial justice framework
Number of subjects: 0
Study 39181556 — intervention group
Group type: COMPARATOR
Intervention: Training with a biomedical framework
Number of subjects: 0
Study 39181597 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 2·4 mg
Number of subjects: 17604
Study 39181597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17604
Study 39181887 — intervention group
Group type: EXPERIMENTAL
Intervention: TBI-223 (daily doses of 1200-2400 mg)
Number of subjects: 0
Study 39181887 — intervention group
Group type: COMPARATOR
Intervention: BPaL regimen (bedaquiline and pretomanid)
Number of subjects: 0
Study 39181887 — intervention group
Group type: COMPARATOR
Intervention: Linezolid
Number of subjects: 0
Study 39182033 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR) with personalized balance training (90 min/week)
Number of subjects: 258
Study 39182033 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary rehabilitation (PR) alone
Number of subjects: 258
Study 39182033 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR) with balance training
Number of subjects: 258
Study 39182045 — intervention group
Group type: EXPERIMENTAL
Intervention: suPAR > 5.1 ng/mL
Number of subjects: 164
Study 39182045 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of suPAR > 9.8 ng/mL, BMI < 29.3 kg/m2, PSI > 106.5
Number of subjects: 164
Study 39182057 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilisation Initiative (MI) with formal education of clinical staff
Number of subjects: 596
Study 39182135 — intervention group
Group type: EXPERIMENTAL
Intervention: Rad-Score developed using diffusion-weighted imaging (DWI)
Number of subjects: 356
Study 39182135 — intervention group
Group type: EXPERIMENTAL
Intervention: Rad-Signature incorporating clinical parameters
Number of subjects: 356
Study 39182135 — intervention group
Group type: EXPERIMENTAL
Intervention: Rad-Score
Number of subjects: 356
Study 39182135 — intervention group
Group type: COMPARATOR
Intervention: ESMO risk groups
Number of subjects: 356
Study 39182137 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic stents (two 7-Fr double pigtail stents)
Number of subjects: 80
Study 39182137 — intervention group
Group type: COMPARATOR
Intervention: Lumen-apposing metal stents (LAMS)
Number of subjects: 80
Study 39182137 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic stents
Number of subjects: 80
Study 39182315 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate mRNA-1273 vaccination
Number of subjects: 1198
Study 39182315 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SoC)
Number of subjects: 1198
Study 39182315 — intervention group
Group type: COMPARATOR
Intervention: Vaccine Declined
Number of subjects: 1198
Study 39182330 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab plus statin therapy
Number of subjects: 80
Study 39182330 — intervention group
Group type: COMPARATOR
Intervention: Statin therapy
Number of subjects: 80
Study 39182487 — intervention group
Group type: EXPERIMENTAL
Intervention: IV thrombolysis (IVT) in patients on oral anticoagulation
Number of subjects: 170